Needham upgraded TransMedics (TMDX) to Buy from Hold with a $148 price target Needham’s transplant tracker indicates that TransMedics’ U.S. sales are likely to beat consensus in Q3, the analyst tells investors in a research note. The firm also expects the company’s new heart and lung clinical trials and its international expansion to become growth drivers in 2026. Meanwhile, TransMedics’ margins are “increasing rapidly,” which should drive upside to earnings estimates, contends the analyst. Needham thinks the company “has a significant lead in a still significantly underpenetrated market.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- Buy Rating for TransMedics Group: Transformative Organ Care System Enhances Transplant Efficiency and Expands Usable Organ Supply
- TransMedics initiated with a Buy at Jefferies
- Buy Rating for TransMedics Group: Innovative Organ Care System and Promising Growth Prospects
- TransMedics added to ‘Tactical Underperform’ list at Evercore ISI
- TransMedics Group Acquires Aircraft for Organ Transport